

Charlotte Kloft

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2081243/publications.pdf>

Version: 2024-02-01

102
papers

1,861
citations

304368

22
h-index

329751

37
g-index

105
all docs

105
docs citations

105
times ranked

2264
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating prediction methods for glomerular filtration to optimise drug doses in obese and nonobese patients. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2973-2981.	1.1	6
2	A continued learning approach for model-informed precision dosing: Updating models in clinical practice. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 185-198.	1.3	8
3	A versatile high-performance LC-MS/MS assay for the quantification of voriconazole and its N-oxide metabolite in small sample volumes of multiple human matrices for biomedical applications. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 210, 114551.	1.4	4
4	Combination of Pharmacokinetic and Pathogen Susceptibility Information To Optimize Meropenem Treatment of Gram-Negative Infections in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0183121.	1.4	4
5	Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism. <i>Pharmaceutics</i> , 2022, 14, 477.	2.0	4
6	Exploring Dried Blood Spot Cortisol Concentrations as an Alternative for Monitoring Pediatric Adrenal Insufficiency Patients: A Model-Based Analysis. <i>Frontiers in Pharmacology</i> , 2022, 13, 819590.	1.6	2
7	Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients. <i>Clinical Pharmacokinetics</i> , 2022, 61, 655-672.	1.6	4
8	Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools. <i>Antibiotics</i> , 2022, 11, 758.	1.5	2
9	Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2021, 9, 91-101.	1.6	14
10	Perspectives on Model-informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 29-36.	2.3	35
11	Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2374-2384.	1.1	6
12	Role of TDM-based dose adjustments for taxane anticancer drugs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 306-316.	1.1	7
13	Decoding (patho-)physiology of the lung by advanced in vitro models for developing novel anti-infectives therapies. <i>Drug Discovery Today</i> , 2021, 26, 148-163.	3.2	6
14	Therapeutic drug monitoring of oral targeted antineoplastic drugs. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 441-464.	0.8	110
15	Quantification of microdialysis related variability in humans: Clinical trial design recommendations. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 157, 105607.	1.9	12
16	Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies. <i>Pharmaceutics</i> , 2021, 14, 115.	1.7	4
17	Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line. <i>Cells</i> , 2021, 10, 716.	1.8	7
18	Reinforcement learning and Bayesian data assimilation for model-informed precision dosing in oncology. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 241-254.	1.3	17

#	ARTICLE	IF	CITATIONS
19	Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Reponse Exemplified by Levofloxacin. <i>Pharmaceutical Research</i> , 2021, 38, 381-395.	1.7	7
20	A Model-Based Pharmacokinetic/Pharmacodynamic Analysis of the Combination of Amoxicillin and Monophosphoryl Lipid A Against <i>S. pneumoniae</i> in Mice. <i>Pharmaceutics</i> , 2021, 13, 469.	2.0	2
21	Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients. <i>Antibiotics</i> , 2021, 10, 468.	1.5	5
22	The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of Pneumonia. <i>Pharmaceutics</i> , 2021, 13, 601.	2.0	1
23	Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups. <i>Cancers</i> , 2021, 13, 2432.	1.7	1
24	Quantification of persister formation of <i>Escherichia coli</i> leveraging electronic cell counting and semi-mechanistic pharmacokinetic/pharmacodynamic modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2088-2096.	1.3	6
25	CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications. <i>Archives of Toxicology</i> , 2021, 95, 2867-2870.	1.9	2
26	Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant <i>Escherichia coli</i> . <i>Antibiotics</i> , 2021, 10, 615.	1.5	4
27	Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2114-2120.	1.3	10
28	Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. <i>Cancers</i> , 2021, 13, 2782.	1.7	21
29	Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics. <i>Pharmaceutics</i> , 2021, 13, 1380.	2.0	4
30	Cost-effectiveness of oral anticancer drugs and associated individualised dosing approaches in patients with cancer: protocol for a systematic review. <i>BMJ Open</i> , 2021, 11, e047173.	0.8	1
31	No clinically relevant removal of meropenem by cytokine adsorber CytoSorb® in critically ill patients with sepsis or septic shock. <i>Intensive Care Medicine</i> , 2021, 47, 1332-1333.	3.9	11
32	Target Site Pharmacokinetics of Meropenem: Measurement in Human Explanted Lung Tissue by Bronchoalveolar Lavage, Microdialysis, and Homogenized Lung Tissue. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0156421.	1.4	6
33	Rationale of a lower dexamethasone dose in prenatal congenital adrenal hyperplasia therapy based on pharmacokinetic modelling. <i>European Journal of Endocrinology</i> , 2021, 185, 365-374.	1.9	8
34	Microdialysis sampling to monitor target-site vancomycin concentrations in septic infants: a feasible way to close the knowledge gap. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106405.	1.1	6
35	The Biosynthetic Monophosphoryl Lipid A Enhances the Therapeutic Outcome of Antibiotic Therapy in Pneumococcal Pneumonia. <i>ACS Infectious Diseases</i> , 2021, 7, 2164-2175.	1.8	2
36	Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. <i>Cancers</i> , 2021, 13, 6281.	1.7	8

#	ARTICLE	IF	CITATIONS
37	EGb 761 [®] Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer's [™] s Dementia [®] Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial. Healthcare (Switzerland), 2021, 9, 1678.	1.0	3
38	Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing [®] A Translational Example for Intensive Care Units. Pharmaceutics, 2021, 13, 2128.	2.0	3
39	Bayesian Data Assimilation to Support Informed Decision Making in Individualized Chemotherapy. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 153-164.	1.3	21
40	Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 430-438.	1.3	5
41	Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 628-638.	1.3	6
42	What is the Impact of Do NLME Publications Have Outside Our Community?. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 191-194.	1.3	1
43	Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. Clinical Pharmacology and Therapeutics, 2020, 108, 661-670.	2.3	17
44	Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1729-e1740.	1.8	18
45	Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen. Frontiers in Pharmacology, 2020, 11, 283.	1.6	19
46	Linezolid Concentrations in Plasma and Subcutaneous Tissue are Reduced in Obese Patients, Resulting in a Higher Risk of Underdosing in Critically Ill Patients: A Controlled Clinical Pharmacokinetic Study. Journal of Clinical Medicine, 2020, 9, 1067.	1.0	13
47	Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study. Annals of Intensive Care, 2020, 10, 48.	2.2	13
48	Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children. European Journal of Endocrinology, 2020, 183, 357-368.	1.9	10
49	Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients [®] A Controlled Clinical Trial. Antibiotics, 2020, 9, 931.	1.5	14
50	Response to Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia [™] . European Journal of Endocrinology, 2020, 183, L29-L30.	1.9	0
51	Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metabolism Reviews, 2019, 51, 247-265.	1.5	41
52	Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis. International Journal of Antimicrobial Agents, 2019, 54, 309-317.	1.1	48
53	Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice. Journal of Clinical Pharmacology, 2019, 59, 1405-1414.	1.0	4
54	Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial. Journal of Antimicrobial Chemotherapy, 2019, 74, 2335-2340.	1.3	15

#	ARTICLE	IF	CITATIONS
55	The circadian rhythm of corticosteroid-binding globulin has little impact on cortisol exposure after hydrocortisone dosing. <i>Clinical Endocrinology</i> , 2019, 91, 33-40.	1.2	9
56	Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. <i>Pharmaceutical Statistics</i> 17 (5):593-606, Sep/Oct 2018, DOI: 10.1002/pst.1873. <i>Pharmaceutical Statistics</i> , 2019, 18, 278-281.	0.7	1
57	A rapid, simple and sensitive liquid chromatography tandem mass spectrometry assay to determine amoxicillin concentrations in biological matrix of little volume. <i>Talanta</i> , 2019, 201, 253-258.	2.9	9
58	High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 131, 218-229.	1.9	12
59	Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 235-242.	1.0	4
60	Adherence to tamoxifen in breast cancer patients: What role does the pharmacist play in German primary care?. <i>Canadian Pharmacists Journal</i> , 2019, 152, 28-34.	0.4	3
61	Drug combinations and impact of experimental conditions on relative recovery in in vitro microdialysis investigations. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 127, 252-260.	1.9	14
62	Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1330-1339.	1.3	63
63	Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2018, 57, 229-242.	1.6	21
64	In search of a standard when analyzing medication adherence in patients with heart failure using claims data: a systematic review. <i>Heart Failure Reviews</i> , 2018, 23, 63-71.	1.7	25
65	Understanding and reducing complex systems pharmacology models based on a novel input-response index. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 139-157.	0.8	4
66	Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults. <i>Clinical Pharmacokinetics</i> , 2018, 57, 515-527.	1.6	15
67	Cytokine and Chemokine Recovery Is Increased by Colloid Perfusates during Dermal Microdialysis. <i>Materials</i> , 2018, 11, 682.	1.3	1
68	Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes. <i>Canadian Respiratory Journal</i> , 2018, 2018, 1-11.	0.8	174
69	Pharmacokinetics of the Inhaled Selective Glucocorticoid Receptor Modulator AZD5423 Following Inhalation Using Different Devices. <i>AAPS Journal</i> , 2017, 19, 865-874.	2.2	12
70	Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small Cell Lung Cancer Receiving Erlotinib Treatment. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 309-315.	1.2	17
71	Impact of altered endogenous IgG on unspecific mAb clearance. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 351-374.	0.8	5
72	Quality of compounded hydrocortisone capsules used in the treatment of children. <i>European Journal of Endocrinology</i> , 2017, 177, 239-242.	1.9	37

#	ARTICLE	IF	CITATIONS
73	Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 347-358.	1.3	27
74	Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1609-1613.	0.8	13
75	Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration. <i>AAPS Journal</i> , 2017, 19, 223-233.	2.2	25
76	Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 617-633.	1.6	47
77	Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study. <i>Critical Care</i> , 2017, 21, 263.	2.5	52
78	Patients' handling of a standardized medication plan: a pilot study and method development. <i>Patient Preference and Adherence</i> , 2016, 10, 621.	0.8	16
79	Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 739-753.	1.1	14
80	Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 538-552.	1.1	30
81	Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer – Proof of concept towards a systems pharmacology approach. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 94, 20-32.	1.9	22
82	Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 307-315.	1.0	35
83	Systems pharmacology in drug development and therapeutic use – A forthcoming paradigm shift. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 94, 1-3.	1.9	21
84	Evaluating patients' comprehensibility of a standardized medication plan. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1229-1237.	0.8	19
85	Simultaneous determination and stability studies of linezolid, meropenem and vancomycin in bacterial growth medium by high-performance liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1028, 242-248.	1.2	29
86	Evolution of a mini-scale biphasic dissolution model: Impact of model parameters on partitioning of dissolved API and modelling of in vivo-relevant kinetics. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 105, 166-175.	2.0	29
87	Concentration-response studies and modelling of the pharmacodynamics of linezolid: <i>Staphylococcus aureus</i> versus <i>Enterococcus faecium</i> . <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 54-60.	1.1	11
88	TDMx: A novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 442-444.	1.1	59
89	Novel non-substrate modulators of the transmembrane efflux pump P-glycoprotein (ABCB1). <i>MedChemComm</i> , 2015, 6, 860-866.	3.5	2
90	Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against <i>Staphylococcus aureus</i> . <i>Pharmaceutical Research</i> , 2015, 32, 2410-2418.	1.7	37

#	ARTICLE	IF	CITATIONS
91	Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs. <i>AAPS Journal</i> , 2015, 17, 853-870.	2.2	68
92	Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships of Monoclonal Antibodies in Children. <i>Clinical Pharmacokinetics</i> , 2015, 54, 35-80.	1.6	34
93	Unbound fraction of ertapenem in intensive care unit patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3108-3111.	1.3	20
94	In vitro microdialysis recovery and delivery investigation of cytokines as prerequisite for potential biomarker profiling. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 57, 48-59.	1.9	17
95	Population pharmacokinetics meets microdialysis: Benefits, pitfalls and necessities of new analysis approaches for human microdialysis data. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 57, 68-73.	1.9	11
96	Pilot Investigation on Long-Term Subcutaneous Microdialysis: Proof of Principle in Humans. <i>AAPS Journal</i> , 2013, 15, 95-103.	2.2	16
97	Population Pharmacokinetic Analysis of a Nevirapine-Based HIV-1 Prevention of Mother-to-Child Transmission Program in Uganda to Assess the Impact of Different Dosing Regimens for Newborns. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 294-304.	1.0	6
98	Pharmacometrics and systems biology in oncology: Is there an intersection?. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 51, 89-90.	0.3	1
99	Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: Comparison across Anticancer Drugs. <i>Clinical Cancer Research</i> , 2006, 12, 5481-5490.	3.2	78
100	Toxicity of High-Dose Carboplatin: Ultrafiltered and Not Total Plasma Pharmacokinetics Is of Clinical Relevance. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 762-773.	1.0	14
101	Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 134-140.	1.1	19
102	Separation and identification of platinum adducts with DNA nucleotides by capillary zone electrophoresis and capillary zone electrophoresis coupled to mass spectrometry. <i>Electrophoresis</i> , 2001, 22, 97-103.	1.3	51